|(what is this?)|
Gomiliximab is a monoclonal antibody acting as an immunosuppressive drug for the treatment of allergic asthma. It targets the low affinity IgE receptor (FcεRII or CD23). The drug is a chimeric antibody from Macaca irus and Homo sapiens.
This drug was developed by IDEC Pharmaceuticals Corporation.
- Statement On A Nonproprietary Name Adopted By The Usan Council - Gomiliximab, American Medical Association.
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|